Condition: Lymphoma (Non-Hodgkin's Lymphoma) · Sponsor: Ruijin Hospital
This study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.
This description comes directly from the study's public registry record.
Shu-Bei Wang, MD · +86-021-64370045 · wangshubei@163.com
Gang Cai, MD · +86-021-64370045 · cg11855@rjh.com.cn
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07628738